Evidence map›Paper›PMID 34083436›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2021

Dopaminergic neuromodulation of prefrontal cortex activity requires the NMDA receptor coagonist d-serine.

Glenn Dallérac, Xia Li, Pierre Lecouflet, Nadège Morisot, Silvia Sacchi, Rachel Asselot, Thu Ha Pham, Brigitte Potier, David J G Watson, Staffan Schmidt and 15 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. UntargetedTranslational psychiatry · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. International journal of molecular sciences · 2022
    Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 8 institutions in 4 countries.

Glenn DalléracCentre de Recherche en Neurobiologie et Neurophysiologie de Marseille, UMR 7286, CNRS, Aix-Marseille Université, 13344 Marseille, France; glenn.dallerac@universite-paris-saclay.fr jean-pierre.mothet@universite-paris-saclay.fr.ORCID 0000-0002-4518-4099
Xia LiUniversité Paris-Saclay, CNRS, Institut des Neurosciences Paris-Saclay, 91190, Gif-sur-Yvette, France.
Pierre LecoufletUniversité Paris-Saclay, CNRS, École Normale Supérieure Paris-Saclay, CentraleSupélec, Laboratoire LuMin, UMR 2036, 91190 Gif-sur-Yvette, France.
Nadège MorisotInstitut de Neurosciences Cognitives et Intégratives d'Aquitaine, UMR 5287, Université de Bordeaux, CNRS, 33076 Bordeaux, France.ORCID 0000-0003-1674-9406
Silvia SacchiThe Protein Factory 2.0, Dipartimento di Biotecnologie e Scienze della Vita, Università degli Studi dell'Insubria, 21100 Varese, Italy.
Rachel AsselotINSERM UMR-S-1075, Université de Caen Normandie, 14000 Caen, France.
Thu Ha PhamLaboratoire de Neuropharmacologie, Centre de Recherche en Epidémiologie et Santé des Populations, Faculté de Pharmacie, INSERM, Université Paris-Saclay, F-92296 Chatenay-Malabry, France.
Brigitte PotierUniversité Paris-Saclay, CNRS, École Normale Supérieure Paris-Saclay, CentraleSupélec, Laboratoire LuMin, UMR 2036, 91190 Gif-sur-Yvette, France.ORCID 0000-0002-9235-7298
David J G WatsonSchool of Life Sciences, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, United Kingdom.
Staffan SchmidtPronexus Analytical AB, 167 33 Bromma, Sweden.
Grégoire LevasseurCentre de Recherche en Neurobiologie et Neurophysiologie de Marseille, UMR 7286, CNRS, Aix-Marseille Université, 13344 Marseille, France.
Pascal FossatInstitut des Maladies Neurodégénératives, UMR 5293, Université de Bordeaux, CNRS, 33077 Bordeaux, France.ORCID 0000-0001-5117-0817
Andrey BesedinINSERM UMR-S-1075, Université de Caen Normandie, 14000 Caen, France.
Jean-Michel RivetCentre for Thérapeutique Innovation in Neuropsychiatry, Institut de Recherche Servier, 78290 Croissy-sur-Seine, Paris, France.
Joseph T CoyleDepartment of Psychiatry, Harvard Medical School, Boston, MA 02115.ORCID 0000-0002-0702-1395
Ginetta ColloDivision of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, 25125 Brescia, Italy.ORCID 0000-0003-1888-5049
Loredano PollegioniThe Protein Factory 2.0, Dipartimento di Biotecnologie e Scienze della Vita, Università degli Studi dell'Insubria, 21100 Varese, Italy.ORCID 0000-0003-1733-7243
Jan KehrPronexus Analytical AB, 167 33 Bromma, Sweden.
Micaela GalanteUniversité Paris-Saclay, CNRS, Institut des Neurosciences Paris-Saclay, 91190, Gif-sur-Yvette, France.
Kevin C FoneSchool of Life Sciences, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, United Kingdom.ORCID 0000-0001-8760-2167
Alain M GardierLaboratoire de Neuropharmacologie, Centre de Recherche en Epidémiologie et Santé des Populations, Faculté de Pharmacie, INSERM, Université Paris-Saclay, F-92296 Chatenay-Malabry, France.ORCID 0000-0002-0320-4880
Thomas FreretINSERM UMR-S-1075, Université de Caen Normandie, 14000 Caen, France.ORCID 0000-0002-4446-4451
Angelo ContarinoInstitut de Neurosciences Cognitives et Intégratives d'Aquitaine, UMR 5287, Université de Bordeaux, CNRS, 33076 Bordeaux, France.ORCID 0000-0002-7286-6941
Mark J MillanCentre for Thérapeutique Innovation in Neuropsychiatry, Institut de Recherche Servier, 78290 Croissy-sur-Seine, Paris, France.
Jean-Pierre MothetCentre de Recherche en Neurobiologie et Neurophysiologie de Marseille, UMR 7286, CNRS, Aix-Marseille Université, 13344 Marseille, France; glenn.dallerac@universite-paris-saclay.fr jean-pierre.mothet@universite-paris-saclay.fr.ORCID 0000-0003-4991-0614
Centre National de la Recherche Scientifique · FRInserm · FRÉcole Normale Supérieure Paris-Saclay · FRServier (France) · FRUniversity of Insubria · ITUniversity of Nottingham · GBHarvard University · USUniversity of Brescia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prefrontal control of cognitive functions critically depends upon glutamatergic transmission and N-methyl D-aspartate (NMDA) receptors, the activity of which is regulated by dopamine. Yet whether the NMDA receptor coagonist d-serine is implicated in the dopamine-glutamate dialogue in the prefrontal cortex (PFC) and other brain areas remains unexplored. Here, using electrophysiological recordings, we show that d-serine is required for the fine-tuning of glutamatergic neurotransmission, neuronal excitability, and synaptic plasticity in the PFC through the actions of dopamine at D

Indexed as

AnimalsDopamineGlutamic AcidMaleMiceMice, KnockoutPrefrontal CortexRacemases and EpimerasesReceptors, DopamineReceptors, N-Methyl-D-AspartateSchizophreniaSerineSerine RacemaseSynaptic TransmissionDopamineGlutamic AcidRacemases and EpimerasesReceptors, DopamineReceptors, N-Methyl-D-AspartateSerineSerine RacemaseD1- and D2-type receptorsd-serineNMDA receptorsschizophreniaserine racemase knockout mice

Identifiers

PMID34083436
PMCPMC8201892
OpenAlexW3164917191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.